

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-9. (Cancelled).

Claim 10. (Previously presented) A mutant *ras* peptide comprising:
an amino acid sequence of at least 8 amino acids, from the sequence consisting
of Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃ Gly Val Gly Lys Ser (SEQ ID NO:15);
wherein Xaa₁ is the amino acid lysine or tyrosine;
wherein Xaa₂ is an amino acid;
wherein Xaa₃ is selected from the group consisting of aspartic acid, valine,
cysteine, alanine, arginine, and serine;
wherein when Xaa₂ is valine, Xaa₁ is tyrosine
and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T
lymphocyte immune response.

Claim 11. (previously presented) The mutant *ras* peptide of claim 10 or 72,
wherein the peptide comprises an amino acid sequence of 13 amino acids.

Claim 12. (previously presented) The mutant *ras* peptide of claim 10 or 72,
wherein the peptide comprises an amino acid sequence of 10 amino acids.

Claim 13. (previously presented) The mutant *ras* peptide of claim 10 or 72,
wherein Xaa₁ is tyrosine.

Claim 14. (previously presented) The mutant *ras* peptide of claim 10 or 72,
wherein Xaa₂ is selected from the group consisting of valine, tryptophan, leucine,
tyrosine, and phenylalanine.

Claim 15. (previously presented) The mutant *ras* peptide of claim 10 or 72 wherein Xaa₁ is tyrosine, and Xaa₃ is aspartic acid.

Claims 16-24. (canceled).

Claim 25. (previously presented) A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide claim 10 or 72 and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

Claim 26. (canceled).

Claim 27. (previously presented) An immunogen for eliciting a mutant *ras* peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim 10 or 72, wherein the immunogen elicits a mutant *ras* peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response.

Claims 28-31. (canceled).

Claim 32. (previously presented) A pharmaceutical composition comprising the mutant *ras* peptide of claim 10 or 72 and a pharmaceutically acceptable carrier.

Claim 33 (previously presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

Claim 34. (previously presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claims 35-65. (canceled).

Claim 66. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, *Pseudomonas* exotoxin A, and poly-L-lysine.

Claim 67. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is tetanus toxoid.

Claim 68. (previously presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

Claim 69. (canceled).

Claim 70. (previously presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF, β 2-microglobulin, or combinations thereof.

Claim 71. (previously presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claim 72. (currently amended) A mutant *ras* peptide comprising:
an amino acid sequence of at least 8 amino acids, ~~wherein said amino acid~~
from the sequence ~~comprises~~ consisting of Tyr Xaa₁ Leu Xaa₂ Val Val Gly Ala Xaa₃
Gly Val Gly Lys Ser (SEQ ID NO:16);
wherein Xaa₁ is the amino acid lysine or tyrosine;
wherein Xaa₂ is an amino acid;
wherein Xaa₃ is selected from the group consisting of aspartic acid, valine,
cysteine, alanine, arginine, and serine;
wherein when Xaa₂ is valine, Xaa₁ is tyrosine

and said peptide elicits a peptide-specific human CD8⁺ cytotoxic T lymphocyte immune response.